Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform.Light Up your Portfolio with Spark:Easily identify ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP – Free Report) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Q4 2024. Management View. CEO Joe Todisco highlighted the commercial success of DefenCath, noting net revenue of $31.2 million for Q4 ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

CorMedix (NASDAQ: CRMD) Q4 2024 Earnings Call Mar 25, 2025, 8:30 a.m. ET Good day, and welcome to the CorMedix Inc.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...